Stockreport

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics, Inc.  (CYTH) 
PDF Two posters presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024Pivotal TransportNPC™ study is the most comprehensive ongo [Read more]